Probi agreement enhanced to strengthen alliance

28 October 2025 Probi agreement enhanced to strengthen alliance BLIS Technologies Limited (NZX: BLT) has signed an agreement with Probi AB (Probi) to enhance their collaborative efforts in the global probiotic market. This agreement extends the existing Technology License & Distribution Agreement and provides Probi exclusive rights to BLIS K12 and BLIS M18 across the USA, Canada, and certain EMEA markets. For the first time, this agreement introduces pet nutrition into Probi's licensed territories, tapping into the burgeoning pet health market and responding to increasing consumer demand for high-quality probiotic solutions for pets. “We are excited to deepen our partnership with Probi,” said Scott Johnson, CEO. “This agreement not only strengthens our foothold in human wellbeing but also aligns with the growing opportunity to provide innovative solutions in pet health.” This collaboration underscores our shared vision to lead in the rapidly expanding probiotic market and deliver exceptional value to our customers and stakeholders. Ends For further information, please contact: Scott Johnson Chief Executive Officer +64 21 488 831 About BLIS Technologies Ltd Delivering proven health benefits through evidence-based, advanced probiotics BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including ears, nose, and throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS products are sold throughout New Zealand and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at www.blis.co.nz. Website: www.blis.co.nz Instagram: @blisprobiotics #blisk12 #blism18 Facebook: @BLISProbiotics